Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa

Fig. 3

Percentage of the 60 multidrug-resistant P. aeruginosa isolates for which combined treatment with 20 mg/L rifampicin reduced the MIC compared to imipenem, meropenem or doripenem alone, stratified by the type of porin mutation (the 21 isolates with a frameshift porin mutation; the 39 isolates with a premature stop codon porin mutation)

Back to article page